Skip to main content
Philogen logo

Philogen — Investor Relations & Filings

Ticker · PHIL ISIN · IT0005373789 LEI · 81560009EA1577917768 XMIL Manufacturing
Open in API
Filings indexed 377 across all filing types
Latest filing 2023-11-07 Earnings Release
Country IT Italy
Listing XMIL PHIL

About Philogen

https://www.philogen.com

Philogen is a clinical-stage biotechnology company focused on the discovery and development of novel biopharmaceutical products for the treatment of cancer and other serious conditions associated with angiogenesis. Founded in 1996, the company's core strategy is based on innovating targeted therapies, such as antibody-cytokine fusions, which are designed to selectively deliver therapeutic agents to the site of disease. This approach aims to increase efficacy while reducing toxicity. Philogen operates as an integrated company with capabilities in research, GMP manufacturing, and clinical development of its proprietary product pipeline.

Recent filings

Filing Released Lang Actions
Il Consiglio Di Amministrazione approva la Posizione Finanziaria Netta relativa al Terzo Trimestre 2023
Earnings Release Classification · 98% confidence The document is titled 'COMUNICATO STAMPA' (Press Release) and explicitly states that the Board of Directors approved the Net Financial Position for the Third Quarter of 2023 ('TERZO TRIMESTRE 2023') and provided updates on clinical trials. It includes a detailed table showing the Net Financial Position as of September 30, 2023, compared to previous quarters, and discusses operational progress. This structure—a press release summarizing period-end financial metrics (Q3) and operational updates—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses heavily on the financial position summary and management commentary, it aligns best with the initial announcement of periodical financial results. The document is a press release announcing the Q3 results, which fits the definition of an Earnings Release (ER). It is not the full, comprehensive report (which would be an IR or 10-Q/10-K equivalent, but IR is the closest fit for a non-US comprehensive quarterly report, though ER is better for the initial announcement). Given the format as a 'COMUNICATO STAMPA' focusing on key financial figures (Net Financial Position) and operational milestones, 'ER' is the most appropriate classification. Q3 2023
2023-11-07 Italian
Allegato 3F - Ottobre 2023
Director's Dealing Classification · 99% confidence The document is titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI" / "MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER'S SECURITIES". It details specific transactions (purchases, indicated by 'A' for Acquisto/Buy in column 3.1) conducted by the issuer (PHILOGEN S.p.A.) in its own shares during October 2023. This structure and content directly correspond to reporting insider or related-party transactions in securities. Among the provided definitions, 'Director's Dealing' (DIRS) is the closest fit for reporting personal share transactions by directors/executives, although this specific form seems to be a mandatory disclosure for transactions involving the issuer itself or related parties, often mandated by market regulators (like CONSOB in Italy, given the Italian language). Since the document explicitly details transactions in the issuer's own securities by a party related to the issuer (Section 1 identifies the party as the Issuer itself, which is unusual but points to a mandatory disclosure of share movement), and the closest category covering executive/insider trading is DIRS, I will classify it as such. However, given the specific nature of the form (Schema di Comunicazione delle Operazioni sui Titoli), it is a regulatory filing concerning insider transactions. DIRS is the best fit among the options for reporting transactions by insiders/directors.
2023-11-06 Italian
2023 10 23 - CS settimanale acquisto azioni proprie ITA
Transaction in Own Shares Classification · 100% confidence The document is titled "AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE" (Update on the Share Buyback Program) and details the number of shares repurchased by Philogen S.p.A. between October 16, 2023, and October 20, 2023. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The code for this is POS. The document is a detailed report of the transactions, not merely an announcement that a report is forthcoming, thus ruling out RPA or RNS.
2023-10-23 Italian
2023 10 16 - CS settimanale acquisto azioni proprie ITA
Transaction in Own Shares Classification · 100% confidence The document is titled "AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE" (Update on the Share Buyback Program) and details the number of own shares purchased during a specific period (October 9 to October 13, 2023), including daily transaction logs and total holdings. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares. This matches the definition for 'Transaction in Own Shares' (Code: POS). It is not a general earnings release (ER), a comprehensive quarterly report (IR), or a proxy statement (PSI).
2023-10-16 Italian
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective for patients with locally advanced fully resectable melanoma (Price Sensitive)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 16, 2023, announcing positive topline results from the Phase III PIVOTAL clinical trial for the drug Nidlegy™. It details the primary endpoint achievement (Recurrence-Free Survival improvement), safety profile, and future plans, including presenting results at a medical meeting and submitting them to regulatory authorities. This content is characteristic of an initial announcement of key clinical trial outcomes, which falls under the scope of an Earnings Release (ER) if it were a periodic financial report, but since it is a specific clinical trial result announcement, it is best classified as an Investor Presentation (IP) or, more broadly, a Regulatory Filing (RNS) if it were a formal submission. However, given the structure—a detailed announcement of clinical data intended for investors and the public, often preceding a formal presentation or regulatory filing—it strongly aligns with the purpose of an Investor Presentation (IP) or a general press release about operational/clinical progress. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a clinical result announcement, 'IP' (Investor Presentation) is a strong fit as it contains detailed data summaries and commentary from management. It is not a full report (10-K, IR), nor is it just a notice of publication (RPA). Given the depth of the clinical data summary, IP is the most appropriate specific category for this type of corporate communication.
2023-10-16 English
Nidlegy™ ha raggiunto positivamente l'obiettivo primario dello studio di Fase III PIVOTAL in pazienti con melanoma localmente avanzato completamente resecabile (Price Sensitive)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 16, 2023, announcing positive results from a Phase III clinical study (PIVOTAL) for a drug called Nidlegy™. It details the primary endpoint achievement (Recurrence-Free Survival improvement), safety profile, and future plans to present results at a medical congress and submit them to regulatory authorities. This content strongly aligns with an initial announcement of key financial/clinical results, which is the definition of an Earnings Release (ER) in a broad sense for biotech/pharma, or more specifically, a press release announcing significant clinical trial data. Since the provided categories include 'Earnings Release (ER)' for periodical financial results and this is a major clinical/business update, and there is no specific category for 'Clinical Trial Results Announcement', ER is the closest fit for a major periodic business update announcement. However, given the context of financial reporting, this is a major corporate announcement regarding R&D success, which often precedes formal financial filings. Since it is a detailed announcement of results and not just a notice that a report is coming, it is not RPA or RNS. It is a comprehensive announcement of a major corporate event (clinical trial success). In the context of financial reporting databases, major clinical trial success announcements are often categorized under the closest equivalent to an 'Earnings Release' or a general 'Regulatory Filing' if no better fit exists. Given the detail, it is more than just an ER (which is usually just key numbers). It is a detailed corporate announcement. If we must choose from the list, and recognizing this is a major corporate milestone announcement, 'ER' (Earnings Release) is often used broadly for major periodic results announcements, or 'RNS' (Regulatory Filings) as a catch-all. Since it is a detailed announcement of a major corporate event (clinical trial success), and not a standard quarterly financial report, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fallback for a significant, non-standard corporate disclosure that isn't a formal financial report (10-K, IR, MRQ).
2023-10-16 Italian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.